1369255-19-5

Basic information

• Product Name: 5-(hydroxymethyl)-2-((6-(trifluoromethyl)pyridin-3-yl)oxy)benzonitrile
• Synonyms: 5-(hydroxymethyl)-2-((6-(trifluoromethyl)pyridin-3-yl)oxy)benzonitrile
• CAS NO: 1369255-19-5
• Molecular Weight: 294.233
• Mol File: 1369255-19-5.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 5-(hydroxymethyl)-2-((6-(trifluoromethyl)pyridin-3-yl)oxy)benzonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(hydroxymethyl)-2-((6-(trifluoromethyl)pyridin-3-yl)oxy)benzonitrile(1369255-19-5)
• EPA Substance Registry System: 5-(hydroxymethyl)-2-((6-(trifluoromethyl)pyridin-3-yl)oxy)benzonitrile(1369255-19-5)

Safety Data

• Hazardous Substances Data: 1369255-19-5(Hazardous Substances Data)

Upstream product

• 1369255-17-3 5-formyl-2-((6-(trifluoromethyl)pyridin-3-yl)oxy)benzonitrile 
• 216766-12-0 5-hydroxy-2-trifluoromethyl pyridine 
• 218301-22-5 2-fluoro-5-formylbenzonitrile 

Relevant articles and documents

PYRIMIDONE COMPOUNDS USED AS LP-PLA2 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS THEREOF

The present invention relates to pyrimidone compounds used as Lp-PLA2 inhibitors and pharmaceutical compositions thereof. The structure of the pyrimidone compounds is represented by general formula (I), wherein R1, R2, Rs

BICYCLIC PYRIMIDONE COMPOUNDS AS INHIBITORS OF LP-PLA2

The present invention relates to novel pyrimido[1,6-a]pyrimidin-6(2H)-one compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease.

TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES

The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease, and/or diabetic macular edema.